期刊
PROSTATE CANCER AND PROSTATIC DISEASES
卷 12, 期 4, 页码 355-360出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/pcan.2009.21
关键词
prostatic neoplasms; utilization; health-care costs
资金
- GlaxoSmithKline Inc
Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13 091, prevention strategies have the potential to reduce health-care costs. Prostate Cancer and Prostatic Diseases (2009) 12, 355-360; doi: 10.1038/pcan.2009.21; published online 26 May 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据